Phase 1 study update
As of September 28th, 2004, 18 patients enrolled
Dose escalation and exploration continuing to identify maximum tolerated dose/recommended phase II dose
Dose frequency to change from weekly to two out of three weeks for doses of 550mg/m2 and above
Biomarker assessment added to current protocol